Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 13, Issue 3, 2017
http://www.tandfonline.com/toc/khvi20/current

Product Review
Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era
Pages 579-587 | Received 02 May 2016, Accepted 01 Oct 2016, Accepted author version posted online: 04 Nov 2016, Published online: 04 Nov 2016
Sachin N. Desai, Lorenzo Pezzoli, Kathryn P. Alberti, Stephen Martin, Alejandro Costa, William Perea & show all
ABSTRACT
Cholera remains an important but neglected public health threat, affecting the health of the poorest populations and imposing substantial costs on public health systems. Cholera can be eliminated where access to clean water, sanitation, and satisfactory hygiene practices are sustained, but major improvements in infrastructure continue to be a distant goal. New developments and trends of cholera disease burden, the creation of affordable oral cholera vaccines (OCVs) for use in developing countries, as well as recent evidence of vaccination impact has created an increased demand for cholera vaccines. The global OCV stockpile was established in 2013 and with support from Gavi, has assisted in achieving rapid access to vaccine in emergencies. Recent WHO prequalification of a second affordable OCV supports the stockpile goals of increased availability and distribution to affected populations. It serves as an essential step toward an integrated cholera control and prevention strategy in emergency and endemic setting.